Neo7Logix COVID-19 Treatment Reduces Viral Infection by More Than 99% in Preclinical Study

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

October 27, 2020

Dr. John Catanzaro, CEO of Neo7Logix USA LLC, today announced that the company has developed an approach to design highly effective specific-matched Anti-Viral Peptide (AVP) sequences that can be used for the treatment and prevention of novel pathogen diseases.

Neo7Logix reports notes a patent-pending method is used to design a pool of synthetic peptides that act in a multi-mechanistic approach to inhibit virus entry points, prevent viral endocytosis (membrane engulfing), block viral unpacking and replication and stimulate the long-term immune response and eradication of the virus.

This “Precision-Based Immuno-Molecular Augmentation (PBIMA)” design method uses artificial intelligence to guide the design of anti-viral peptides based on the target viral genome sequences and available data on the human population HLA (human leukocyte antigen) susceptibility. Neo7Logix has recently completed a preclinical study that demonstrated greater than 99% reduction of viral load in mice infected with mutant coronavirus HCoV-229E using anti-HCoV-229E (COVID-19) PBIMA-SOLVx with no adverse effects. This proof of concept study also revealed remarkable immunomodulatory stimulation of T and B cells for the immune response. Dr. Catanzaro added, “to our knowledge, there currently is no other highly effective treatment for COVID-19.”

The AVP had no Antibody-Dependent Enhancement (ADE) problem because it induced only CD8+/CD4+ response unlike some current prophylactic vaccines in clinical trials.  Existing preclinical data along with computational results show that the AVP designs are non-toxic, non-allergenic and thermostable.

The PBIMA approach can be used to design AVP’s for future novel pathogens in as little as two weeks. Neo7Logix USA LLC is preparing to submit an application to begin clinical trials as soon as possible under the FDA’s Investigational New Drug (IND) program.



Subscribe to Medical Device News Magazine

Related Articles